KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 129 filers reported holding KEROS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,995,340 | -19.6% | 407,633 | +1.4% | 5.15% | +5.1% |
| Q2 2023 | $16,157,101 | +44.9% | 402,118 | +54.0% | 4.90% | +65.7% |
| Q1 2023 | $11,147,219 | +7.9% | 261,059 | +21.4% | 2.96% | +7.6% |
| Q4 2022 | $10,327,133 | +37.1% | 215,059 | +7.4% | 2.75% | +35.8% |
| Q3 2022 | $7,533,000 | +163.6% | 200,229 | +93.6% | 2.03% | +85.5% |
| Q2 2022 | $2,858,000 | -15.5% | 103,429 | +66.2% | 1.09% | -24.1% |
| Q1 2022 | $3,384,000 | +230.1% | 62,229 | +255.2% | 1.44% | +323.2% |
| Q4 2021 | $1,025,000 | +105.0% | 17,518 | +38.7% | 0.34% | +132.9% |
| Q3 2021 | $500,000 | -89.9% | 12,627 | -89.2% | 0.15% | -87.3% |
| Q2 2021 | $4,944,000 | -79.9% | 116,406 | -70.9% | 1.15% | -76.7% |
| Q1 2021 | $24,649,000 | -19.5% | 400,468 | -7.7% | 4.94% | -42.8% |
| Q4 2020 | $30,604,000 | +39.3% | 433,852 | -23.8% | 8.62% | +10.3% |
| Q3 2020 | $21,964,000 | +1.0% | 569,458 | -1.8% | 7.81% | -7.9% |
| Q2 2020 | $21,746,000 | – | 579,744 | – | 8.49% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |